DENVER — Ivermectin 1% cream was safe and effective in treating patients with papulopustular rosacea, according to late-breaking study results presented at the American Academy of Dermatology annual meeting.
“Ivermectin 1% cream has a unique mechanism of action and can be considered an innovative treatment for patients with moderate to severe papulopustular rosacea,” Linda Stein Gold, MD, director of clinical research at Henry Ford Hospital, Detroit, told Healio.com.
Ivermectin 1% cream (IVM 1%) contains “novel anti-inflammatory and anti-parasitic properties,” Gold said.
Linda Stein Gold
Gold and colleagues conducted two identically designed, randomized, double-blind controlled phase 3 studies of IVM 1% or vehicle cream once daily for 12 weeks as treatment in patients with moderate to severe papulopustular rosacea.
More patients in the IVM 1% cohorts (38%-40%) achieved treatment success in both studies, which was IGA “clear” or “almost clear,” at 12 weeks compared with patients treated with vehicle (12%-19%; P<.001, both), respectively. In median reduction of inflammatory lesion counts, IVM 1% demonstrated superiority (75%) to vehicle treatment (50%).
IVM 1% was “statistically significantly superior” for all endpoints from week 4 through week 12 (P<.001), study authors wrote.
Through week 12, treatment-related dermatologic adverse events were reported by fewer patients in the IVM treatment groups (1.5-3.5% vs. 5.7%-6.9%). “Excellent” or “good” rosacea improvement was reported by 66%-69% of patients receiving IVM 1% compared with 34%-39% of patients treated with vehicle. The IVM-treated patients also reported an improved quality of life. -- by Bruce Thiel
For more information:
Gold LS. #S020: The Latest in Dermatology Research Part 1, Innovation in Papulopustular Rosacea Treatment: Efficacy and Safety of Ivermectin 1% Cream. Presented at the 2014 American Academy of Dermatology annual meeting; March 21-25, 2014; Denver.
Disclosure: Stein Gold and fellow researchers received a grant for conducting the studies from Galderma R&D.